T1	p 94 102	diarrhea
T2	p 106 116	children .
T3	p 190 200	children .
T4	p 369 402	acute invasive diarrhea requiring
T5	p 425 442	southern Israel .
T6	p 726 757	infants and children . PATIENTS
T7	p 770 964	From July 1996 through December 1997 , 201 evaluable children ages 6 months to 10 years ( 35 % < 1 year ; 70 % < 3 years ) presenting with acute invasive diarrhea at the Pediatric Emergency Room
T8	p 1194 1235	Shigella , Salmonella , Campylobacter spp
T9	p 2423 2488	ambulatory pediatric patients requiring an emergency room visit .
T10	i 6 75	Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment
T11	i 281 320	antibiotics , intramuscular ceftriaxone
T12	i 665 678	ciprofloxacin
T13	i 999 1025	ciprofloxacin suspension (
T14	i 1047 1061	+ im placebo ;
T15	i 1074 1124	im ceftriaxone ( 50 mg/kg/day + placebo suspension
T16	i 1485 1493	Shigella
T17	i 1803 1816	ciprofloxacin
T18	i 1821 1832	ceftriaxone
T19	i 2110 2123	ciprofloxacin
T20	i 2138 2149	ceftriaxone
T21	i 2293 2315	Oral ciprofloxacin was
T22	i 2355 2366	ceftriaxone
T23	o 94 102	diarrhea
T24	o 241 258	enteric pathogens
T25	o 614 633	efficacy and safety
T26	o 705 722	invasive diarrhea
T27	o 924 932	diarrhea
T28	o 1325 1353	Clinical response and safety
T29	o 1421 1443	isolated 127 pathogens
T30	o 1575 1608	Overall bacteriologic eradication
T31	o 1738 1766	Clinical cure or improvement
T32	o 1857 1883	Serum ciprofloxacin values
T33	o 2056 2083	drug-related adverse events
T34	o 2184 2213	transient . Joint examination
T35	o 2396 2419	acute invasive diarrhea
T36	o 2423 2433	ambulatory